Eugenol
Explore a selection of our essential drug information below, or:
Identification
- Summary
Eugenol is a phenol used for the temporary relief of toothaches.
- Generic Name
- Eugenol
- DrugBank Accession Number
- DB09086
- Background
Eugenol is a naturally occurring phenolic molecule found in several plants such as cinnamon, clove, and bay leaves. It has been used as a topical antiseptic as a counter-irritant and in dental preparations with zinc oxide for root canal sealing and pain control. Although not currently available in any FDA-approved products (including OTC), eugenol has been found to have anti-inflammatory, neuroprotective, antipyretic, antioxidant, antifungal and analgesic properties. Its exact mechanism of action is unknown, however, it has been shown to interfere with action potential conduction. There are a number of unapproved OTC products available containing eugenol that advertise its use for the treatment of toothache.
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 164.2011
Monoisotopic: 164.083729628 - Chemical Formula
- C10H12O2
- Synonyms
- Eugenol
- External IDs
- FEMA NO. 2467
- NSC-209525
- NSC-8895
Pharmacology
- Indication
Eugenol is not currently available in any FDA-approved drug products. There are a number of unapproved OTC products that advertise it for the use of toothache. Eugenol is is also commonly used in combination with zinc oxide in dental procedures for the cementation of temporary prostheses and the temporary restoration of teeth and cavities.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Bruises Combination Product in combination with: Methyl salicylate (DB09543), Levomenthol (DB00825) ••• ••• ••••• Used in combination to treat Insect bites Combination Product in combination with: Methyl salicylate (DB09543), Levomenthol (DB00825) ••• ••• ••••• Used in combination to treat Soreness, muscle Combination Product in combination with: Levomenthol (DB00825), Methyl salicylate (DB09543) ••• ••• ••••• Treatment of Soreness, muscle ••• ••• •••••• •••• •••••••• Used in combination to treat Sprains Combination Product in combination with: Methyl salicylate (DB09543), Levomenthol (DB00825) ••• ••• ••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
The exact mechanism of action of eugenol is unknown. However, eugenol has been shown to interrupt action potentials, which may be involved in its anti-pain activity. Research has also shown eugenol to have anti-inflammatory, neuroprotective, antipyretic, antioxidant, antifungal and analgesic properties.
Target Actions Organism AAmine oxidase [flavin-containing] B inhibitorHumans UEstrogen receptor Not Available Humans UEstrogen receptor beta Not Available Humans UAndrogen receptor antagonistHumans UTransient receptor potential cation channel subfamily V member 3 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image AnaDent Childrens Kanka Gel Gel 12 mg/1g Dental Belmora LLC 2022-11-08 Not applicable US Baby Orajel Naturals Remedy for Teething Pain Relief Gel 12 mg/1g Topical Church & Dwight Co., Inc. 2010-12-15 2012-04-24 US DenTek Eugenol Liquid 850 mg/1mL Dental IIMED MEDICAL MEXICANA S. DE R.L. DE C.V. 2022-10-10 Not applicable US DenTek Eugenol Liquid 850 mg/1mL Dental DenTek Oral Care, Inc. 2015-07-01 Not applicable US DenTek Eugenol Liquid 850 mg/1mL Dental Team Technologies, Inc 2015-07-01 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AMMELTZ YOKO YOKO Massage Cream Eugenol (1.36 g/100g) + Levomenthol (5.44 g/100g) + Methyl salicylate (10.2 g/100g) Cream Topical KOBAYASHI Healthcare (Malaysia) Sdn. Bhd. 2020-09-08 Not applicable Malaysia Anti Paronychia Relief Eugenol (1.7 mg/10mL) + Clove oil (2 mg/10mL) + Shea butter (1.7 mg/10mL) + Thyme (1.7 mg/10mL) + Tocopherol (1.2 mg/10mL) Oil Topical Shantou Youjia E-Commerce Co., Ltd. 2024-02-01 2024-12-31 US BIO-MUSCLAX CREAM Eugenol (1.2 g/100g) + Levomenthol (5.5 g/100g) + Methyl salicylate (11 g/100g) Cream Topical Top Biopharma Sdn Bhd 2020-09-08 Not applicable Malaysia COUNTERPAIN ANALGESIC BALM Eugenol (1.36 %) + Levomenthol (5.44 %) + Methyl salicylate (10.2 %) Ointment Topical HOE PHARMACEUTICALS SDN. BHD. 2020-09-08 Not applicable Malaysia Dry Socket Paste Eugenol (4.16 %) + Acetylsalicylic acid (8.33 %) + Chlorobutanol (1.5 %) Paste Dental Sultan Healthcare 1985-12-31 2004-08-06 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Dry Socket Eugenol (0.0416 g/1g) + Guaiacol (0.0416 g/1g) Paste Dental Dentsply Llc, Professional Division, Trading As "Sultan Healthcare" 1963-01-01 Not applicable US
Categories
- Drug Categories
- Acids, Carbocyclic
- Alkenes
- Allyl Compounds
- Allylbenzene Derivatives
- Anti-Infective Agents
- Benzene Derivatives
- Caffeic Acids
- Cell-mediated Immunity
- Cinnamates
- Compounds used in a research, industrial, or household setting
- Hydrocarbons, Acyclic
- Increased Histamine Release
- Solvents
- Standardized Chemical Allergen
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as methoxyphenols. These are compounds containing a methoxy group attached to the benzene ring of a phenol moiety.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Phenols
- Sub Class
- Methoxyphenols
- Direct Parent
- Methoxyphenols
- Alternative Parents
- Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Hydrocarbon derivatives
- Substituents
- 1-hydroxy-2-unsubstituted benzenoid / Alkyl aryl ether / Anisole / Aromatic homomonocyclic compound / Ether / Hydrocarbon derivative / Methoxybenzene / Methoxyphenol / Monocyclic benzene moiety / Organic oxygen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- phenols, phenylpropanoid, monomethoxybenzene (CHEBI:4917) / Monolignols (C10453) / a monoterpenol, a phenol (CPD-6481)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 3T8H1794QW
- CAS number
- 97-53-0
- InChI Key
- RRAFCDWBNXTKKO-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H12O2/c1-3-4-8-5-6-9(11)10(7-8)12-2/h3,5-7,11H,1,4H2,2H3
- IUPAC Name
- 2-methoxy-4-(prop-2-en-1-yl)phenol
- SMILES
- COC1=C(O)C=CC(CC=C)=C1
References
- General References
- Fonseca DV, Salgado PR, Aragao Neto Hde C, Golzio AM, Caldas Filho MR, Melo CG, Leite FC, Piuvezam MR, Pordeus LC, Barbosa Filho JM, Almeida RN: Ortho-eugenol exhibits anti-nociceptive and anti-inflammatory activities. Int Immunopharmacol. 2016 Sep;38:402-8. doi: 10.1016/j.intimp.2016.06.005. Epub 2016 Jun 27. [Article]
- Park SH, Sim YB, Lee JK, Kim SM, Kang YJ, Jung JS, Suh HW: The analgesic effects and mechanisms of orally administered eugenol. Arch Pharm Res. 2011 Mar;34(3):501-7. doi: 10.1007/s12272-011-0320-z. Epub 2011 May 6. [Article]
- Dal Bo W, Luiz AP, Martins DF, Mazzardo-Martins L, Santos AR: Eugenol reduces acute pain in mice by modulating the glutamatergic and tumor necrosis factor alpha (TNF-alpha) pathways. Fundam Clin Pharmacol. 2013 Oct;27(5):517-25. doi: 10.1111/j.1472-8206.2012.01052.x. Epub 2012 Jul 8. [Article]
- External Links
- Human Metabolome Database
- HMDB0005809
- KEGG Compound
- C10453
- PubChem Compound
- 3314
- PubChem Substance
- 310265013
- ChemSpider
- 13876103
- BindingDB
- 50164168
- 4186
- ChEBI
- 4917
- ChEMBL
- CHEMBL42710
- ZINC
- ZINC000000001411
- PDBe Ligand
- EOL
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Eugenol
- PDB Entries
- 3s0e / 7lid / 7ywu / 7ywv
- FDA label
- Download (1.32 MB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Not Available Inflammations, Endodontic / Operative Dentistry / Pulpitides / Toothache 1 somestatus stop reason just information to hide 4 Active Not Recruiting Treatment Periodontitis, Apical 1 somestatus stop reason just information to hide 3 Completed Treatment Plaque, Dental 1 somestatus stop reason just information to hide 0 Recruiting Treatment Pulpitis dental 1 somestatus stop reason just information to hide 0 Unknown Status Supportive Care Gingival Pigmentation 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Gel Dental 12 mg/1g Oil Topical Gel Topical 12 mg/1g Gel Topical Paste Dental Solution Dental 100 % v/v Liquid Dental 100 % Liquid Oral 850 mg/1mL Liquid Dental Solution / drops Dental 17 mg/1mL Cream Topical Gel Topical 13 mg/1g Gel Topical 8 mg/1g Liquid Topical 850 mg/1mL Kit Cutaneous Ointment Topical Liquid Dental 850 mg/1mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.44 mg/mL ALOGPS logP 2.66 ALOGPS logP 2.61 Chemaxon logS -2.1 ALOGPS pKa (Strongest Acidic) 9.94 Chemaxon pKa (Strongest Basic) -4.9 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 29.46 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 48.79 m3·mol-1 Chemaxon Polarizability 17.9 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 143.1484102 predictedDarkChem Lite v0.1.0 [M-H]- 143.5460102 predictedDarkChem Lite v0.1.0 [M-H]- 142.0151102 predictedDarkChem Lite v0.1.0 [M-H]- 143.9802102 predictedDarkChem Lite v0.1.0 [M-H]- 132.91396 predictedDeepCCS 1.0 (2019) [M+H]+ 143.1022102 predictedDarkChem Lite v0.1.0 [M+H]+ 143.7870102 predictedDarkChem Lite v0.1.0 [M+H]+ 143.3895102 predictedDarkChem Lite v0.1.0 [M+H]+ 143.9674102 predictedDarkChem Lite v0.1.0 [M+H]+ 136.68623 predictedDeepCCS 1.0 (2019) [M+Na]+ 143.3098102 predictedDarkChem Lite v0.1.0 [M+Na]+ 143.4763102 predictedDarkChem Lite v0.1.0 [M+Na]+ 141.8444102 predictedDarkChem Lite v0.1.0 [M+Na]+ 146.22993 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues (PubMed:11049757, PubMed:11134050, PubMed:20493079, PubMed:8316221, PubMed:8665924). Preferentially degrades benzylamine and phenylethylamine (PubMed:11049757, PubMed:11134050, PubMed:20493079, PubMed:8316221, PubMed:8665924)
- Specific Function
- aliphatic amine oxidase activity
- Gene Name
- MAOB
- Uniprot ID
- P27338
- Uniprot Name
- Amine oxidase [flavin-containing] B
- Molecular Weight
- 58762.475 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Essential for MTA1-mediated transcriptional regulation of BRCA1 and BCAS3 (PubMed:17922032). Maintains neuronal survival in response to ischemic reperfusion injury when in the presence of circulating estradiol (17-beta-estradiol/E2) (By similarity)
- Specific Function
- 14-3-3 protein binding
- Gene Name
- ESR1
- Uniprot ID
- P03372
- Uniprot Name
- Estrogen receptor
- Molecular Weight
- 66215.45 Da
References
- Howes MJ, Houghton PJ, Barlow DJ, Pocock VJ, Milligan SR: Assessment of estrogenic activity in some common essential oil constituents. J Pharm Pharmacol. 2002 Nov;54(11):1521-8. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1/ER-alpha, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560)
- Specific Function
- DNA binding
- Gene Name
- ESR2
- Uniprot ID
- Q92731
- Uniprot Name
- Estrogen receptor beta
- Molecular Weight
- 59215.765 Da
References
- Howes MJ, Houghton PJ, Barlow DJ, Pocock VJ, Milligan SR: Assessment of estrogenic activity in some common essential oil constituents. J Pharm Pharmacol. 2002 Nov;54(11):1521-8. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues (PubMed:19022849). Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation (PubMed:20812024). Transcription activation is also down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3
- Specific Function
- androgen binding
- Gene Name
- AR
- Uniprot ID
- P10275
- Uniprot Name
- Androgen receptor
- Molecular Weight
- 99187.115 Da
References
- Ogawa Y, Akamatsu M, Hotta Y, Hosoda A, Tamura H: Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2111-4. doi: 10.1016/j.bmcl.2010.02.059. Epub 2010 Feb 21. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Receptor-activated non-selective calcium permeant cation channel. It is activated by innocuous (warm) temperatures and shows an increased response at noxious temperatures greater than 39 degrees Celsius. Activation exhibits an outward rectification. May associate with TRPV1 and may modulate its activity. Is a negative regulator of hair growth and cycling: TRPV3-coupled signaling suppresses keratinocyte proliferation in hair follicles and induces apoptosis and premature hair follicle regression (catagen)
- Specific Function
- calcium channel activity
- Gene Name
- TRPV3
- Uniprot ID
- Q8NET8
- Uniprot Name
- Transient receptor potential cation channel subfamily V member 3
- Molecular Weight
- 90635.115 Da
References
- Borbiro I, Lisztes E, Toth BI, Czifra G, Olah A, Szollosi AG, Szentandrassy N, Nanasi PP, Peter Z, Paus R, Kovacs L, Biro T: Activation of transient receptor potential vanilloid-3 inhibits human hair growth. J Invest Dermatol. 2011 Aug;131(8):1605-14. doi: 10.1038/jid.2011.122. Epub 2011 May 19. [Article]
Drug created at September 15, 2015 20:13 / Updated at August 26, 2024 19:21